Coronavirus disease(COVID-19)

• Updated as of December 12, 2021

• COVID-19 Vaccination Tool Kit for Health Care Providers The National Advisory Committee on Immunization (NACI) Recommendations on the use of COVID-19 vaccines. The NACI COVID-19 vaccine statement has been updated to reflect current evidence on rates for vaccine-induced immune thrombotic thrombocytopenia (VITT). This update also includes clarifications to existing recommendations on interchangeability within the mRNA vaccine platform.
• Voici une mise à jour récente aux Recommandations sur l’utilisation des vaccins contre la COVID-19 du Comité consultatif national de l’immunisation (CCNI). La déclaration du CCNI sur les vaccins contre la COVID-19 a été mise à jour à la lumière des données actuelles sur les taux de thrombocytopénie thrombotique immunitaire induite par le vaccin (TTIV). Cette mise à jour comprend aussi des clarifications aux recommandations actuelles sur l’interchangeabilité dans la plateforme de vaccin à ARNm.

Upcoming Webinar

NEW! The Public Health Agency of Canada (PHAC) presents a Webinar for Health Care Providers : COVID-19 Vaccine for Pediatric Use in Canada (Monday, December 13, 12:00PM – 1:15PM EST)

General information:  

• News release: https://www.canada.ca/en/public-health/news/2021/11/government-of-canada-introduces-new-measures-to-address-covid-19-omicron-variant-of-concern.htmlStatement from the Public Health Agency of Canada: https://www.canada.ca/en/public-health/news/2021/11/statement-on-the-omicron-variant-of-concern-found-in-ontario.html
• Statement from the Honourable Jean-Yves Duclos, Minister of Health: https://www.canada.ca/en/public-health/news/2021/11/statement-from-minister-duclos-on-first-cases-of-omicron-variant-of-concern-in-canada.html
• Statement from the Government of Ontario: https://news.ontario.ca/en/statement/1001241/ontario-confirms-first-two-cases-of-omicron-variant

• NEW! Update on COVID-19 in Canada: Epidemiology and Modelling
• NEW! Ventilation helps protect against the spread of COVID-19
• NEW! COVID-19 vaccines (5 to 11 year olds): It’s time for kids to make memories again (video)
• Update: Vaccines for children: COVID-19
• Update: Vaccines for COVID-19: How to get vaccinated
• Update: COVID-19: Recommendations for those vaccinated with vaccines not authorized by Health Canada for those staying in Canada to live, work or study
• Update: COVID-19: Proof of vaccination in Canada
• Update: National case definition: Coronavirus disease (COVID-19)
• Update: SARS-CoV-2 variants: National definitions, classifications and public health actions
• Update: COVID-19: Use ArriveCAN to enter Canada
• Update: Apply for an exemption for compassionate reasons: Requirements
• Update: Border measures for air travel
• Update: Animals and COVID-19

• NACI: Rapid response: Updated recommendation on the use of authorized COVID-19 vaccines in individuals aged 12 years and older in the context of myocarditis and pericarditis reported following mRNA COVID-19 vaccine
  • Summary
• NACI: Guidance on booster COVID-19 vaccine doses in Canada – Update December 3, 2021 Summary
• The Public Health Agency of Canada (PHAC) presents a Webinar for Health Care Providers : COVID-19 Vaccine for Pediatric Use in Canada (Monday, December 13, 12:00PM – 1:15PM EST)
• Vaccines for children: COVID-19
• Coronavirus disease (COVID-19): Outbreak update
• Provincial and territorial restrictions

• What we heard report: Records retention consultations related to the clinical trials interim order transition regulations
• NACI Meetings: Summary of Decision
• COVID-19 mask use: Types of masks and respirators
• List of Acts and Regulations (coming into force Nov 21, Nov 30, and Jan 15, 2022)
• COVID-19 summaries of recent evidence
• Product Monograph: Cominarty COVID-19 Vaccine
• Product Monograph: Vaxzevria COVID-19 vaccine
• NACI statement: Interim guidance on booster COVID-19 vaccine doses in Canada Full Statement
• Guidance for market authorization requirements for COVID-19 drugs: Overview
• Summary report of the Federal-Provincial-Territorial Virtual Care Summit
• Vaccine uptake in Canadian adults: Highlights from the 2020-2021 Seasonal Influenza Vaccination Coverage Survey
• Drug and Health Product Submissions Under Review (SUR): New drug submissions under review
• Biosafety advisory: SARS-CoV-2 (Severe acute respiratory syndrome coronavirus 2)
• Quick reference guide on use of COVID-19 vaccines
• Epidemiology and Modelling
• COVID-19: Improving indoor ventilation
• Report of adverse events following immunization (AEFI)
• Recommendations on the use of COVID-19 vaccines
• COVID-19: Life after vaccination
• COVID-19 vaccination in Canada
• COVID-19: Effectiveness and benefits of vaccination
• Planning guidance for immunization clinics for COVID-19 vaccines
• Vaccines for children: COVID-19
• National Advisory Committee on Immunization (NACI) rapid response: Additional dose of COVID-19 vaccine in immunocompromised individuals following 1- or 2- dose primary series   
• Testing for COVID-19: Increasing testing supply · Summary Basis of Decision – Sotrovimab – Health Canada   
• Mental Illness during the Pandemic: Survey on COVID-19 and Mental Health
• PHM Rapid Response Summer 2021 (video) – English Only
• COVID-19 quarantine compliance and enforcement (Compliance Call Campaign 4.0 and 5.0): Privacy compliance evaluation
• Notice: Regulations amending certain regulations concerning drugs and medical devices (shortages)
• Recommendation on the use of mRNA COVID-19 vaccines in adolescents 12 to 17 years of age
• Regulatory Decision Summary: COVID-19 vaccine Moderna – Health Canada (12-17 years of age)
• Moderna COVID-19 vaccine (product page for youth authorization)
• COVID-19 vaccine Moderna factsheet
• Drug and vaccine authorizations for COVID-19: List of applications received
• Drug and vaccine authorizations for COVID-19: List of authorized drugs, vaccines and expanded indications
• COVID-19 vaccination in Canada
• Reported side effects following COVID-19 vaccination in Canada
• List of medical devices for exceptional importation and sale
• Vaccines for children: COVID-19
• Drug and vaccine authorizations for COVID-19: List of applications received
• Drug and vaccine authorizations for COVID-19: List of authorized drugs, vaccines and expanded indications
• Regulations amending certain regulations concerning drugs and medical devices (shortages)
• Medical device shortages: List of shortages
• Pfizer Product Monograph
• Medical device shortages: List of shortages
• Vaccines for COVID-19: How to get vaccinated or register
• Drug and vaccine authorizations for COVID-19: List of applications received
• Moderna COVID-19 vaccine
• COVID-19 vaccination in Canada
• List of medical devices for exceptional importation and sale
• Testing for COVID-19 in vaccinated populations
• Pan-Canadian COVID-19 Testing and Screening Guidance: Technical guidance and implementation plan
• Pan-Canadian virtual care priorities in response to COVID-19
• Industry Advisory Roundtable on COVID-19 testing: Taking stock and looking forward
• COVID-19 vaccine safety and side effects (information about Guillain-Barré syndrome)
• Adjusting public health measures in the context of COVID-19 vaccination
• COVID-19 vaccination in Canada
• Reported side effects following COVID-19 vaccination in Canada
• Rapid testing in the workplace: Information for employees
• Regulatory requirements for UV light-emitting products with COVID-19 claims
• Prescription Drug List (PDL): Sotrovimab (COVID-19)
• SARS-CoV-2 variants: National definitions, classifications and public health actions
• COVID-19: Life after vaccination
• Global Public Health Intelligence Network (GPHIN) Independent Review Panel Final Report
• COVID-19 rapid antigen testing devices that use serial testing for individuals without symptoms: Notice to industry
• iving Summary of SARS-CoV-2 Alpha, Beta and Gamma Variants of Concern
• Highlights from Cycle 2 of the COVID-19 Vaccination Coverage Survey (CVCS)
• Recommendations on the use of COVID-19 Vaccines
• COVID-19: PHAC Modelling Group Report – May 20 2021 Issue
• Summary of National Advisory Committee on Immunization statement of May 28, 2021
• Interchangeability of Authorized COVID-19 Vaccines
• VaccineConnect: IT system for managing vaccination rollout
• Vaccine Injury Support Program
• Vaccines for COVID-19: Shipments and deliveries
• Drug and vaccine authorizations for COVID-19: List of applications received
• COVID-19 Treatments
• COVID-19 medical masks and respirators: Information for health professionals
• COVID-19 mRNA vaccines
• COVID-19 viral vector-based vaccines
• The COVID-19 Public Health Agency of Canada (PHAC) Modelling Group – May 6, 2021 Issue
• National Advisory Committee on Immunization (NACI): Workplan
• Health Canada updates list of medical devices for mandatory reporting of shortages
• Animals and COVID-19
• COVID-19: Support to provinces and territories
• Recommendation on the use of the Pfizer-BioNTech COVID-19 vaccine in adolescents 12 to 18 years of age
• Summary of National Advisory Committee on Immunization statement of May 18, 2021 
• COVID-19 Vaccination Tool Kit for Health Care Providers
• AstraZeneca and COVISHIELD COVID-19 vaccines and the potential risk of thrombosis in combination with thrombocytopenia.
• vaccins contre la COVID 19 d’AstraZeneca et COVISHIELD et le risque potentiel de thrombose associée à une thrombocytopénie.
• Trousse à outils de vaccination pour les fournisseurs de soins de santé.
• Health Canada authorizes Janssen COVID-19 vaccine
• Janssen COVID-19 vaccine: What you should know
• NACI rapid response: Extended dose intervals for COVID-19 vaccines to optimize early vaccine rollout and population protection in Canada
• COVID-19 Variants
• Webinars on immunization clinic planning, and vaccine planning and administration
• Statement from the Council of Chief Medical Officers of Health:  Implementing COVID-19 Vaccination in Canada — Vaccine Dose Interval
• Recommendations on the use of COVID-19 vaccine(s)
• Guidance on the prioritization of initial doses of COVID-19 vaccine(s)
• Guidance for repeated PCR testing in individuals previously positive for COVID-19
• Pfizer-BioNTech COVID-19 vaccine: What you should know
• Pfizer-BioNTech COVID-19 vaccine: Health Canada recommendations for people with serious allergies
• Authorization of Pfizer-BioNTech COVID-19 Vaccine with English-only Carton and Vial Labels
• Canada to receive early access to Moderna COVID-19 vaccine
• COVID-19 mRNA vaccines
• Vaccines and treatments for COVID-19: Progress
• Canada’s COVID-19 Immunization Plan: Saving Lives and Livelihoods
• Health Canada authorizes first COVID-19 vaccine
• COVID-19 immunization: Federal, provincial and territorial statement of common principles
• COVID-19 vaccines and treatments portal – Information on vaccines and treatments authorized for COVID-19, as well as those currently under review.
• International Coalition of Medicines Regulatory Authorities statement on continuation of vaccine trials
• Guidance Documents: https://www.canada.ca/en/public-health/services/diseases/2019-novel-coronavirus-infection/guidance-documents.html
• Chief Public Health Officer of Canada’s Report on the State of Public Health in Canada 2020, From risk to resilience: An equity approach to COVID-19